Beacon launched Brigatinib under the brand name of
Briganix. It is a tablet preparation which is available in two strength 90 mg
and 180 mg respectively.
It is indicated
for the treatment of patients with non small cell lung cancer who have
progressed on or are intolerant to Crizotinib.
To know more visit our product website :